Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses the results of the SWOG S0500 trial, which looked at circulating tumor cell (CTC) levels in patients with metastatic breast cancer.
Brian Leyland-Jones, MBBS, PhD
Advertisement
Articles by Brian Leyland-Jones, MBBS, PhD
Brian Leyland-Jones, MBBS, PhD, gives an overview of a trial that looks at all aspects of sequencing in breast cancer.
Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses the use of erythropoiesis stimulating agents (ESAs) in patients with breast cancer.
Advertisement
Latest Updated Articles
The Use of ESAs in Patients With Breast CancerPublished: September 26th 2013 | Updated:
Sequencing in Breast CancerPublished: October 24th 2013 | Updated:
Results of the SWOG S0500 TrialPublished: December 17th 2013 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
